Evidence map›Paper›PMID 39122833›Full record

ArticleScientific reports2024

Binary classification of copy number alteration profiles in liquid biopsy with potential clinical impact in advanced NSCLC.

Valeria Tosello, Angela Grassi, Dominic Rose, Loc Carlo Bao, Elisabetta Zulato, Chiara Dalle Fratte, Maurizio Polano, Paola Del Bianco, Giulia Pasello, Valentina Guarneri and 2 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Valeria Tosello *Basic and Translational Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Angela Grassi *Clinical Research Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Dominic RoseSequencing Solutions, Roche Diagnostics Deutschland GmbH, Mannheim, Germany.
Loc Carlo BaoDepartment of Surgery, Oncology, Gastroenterology, University of Padova, Padua, Italy.
Elisabetta ZulatoBasic and Translational Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Chiara Dalle FratteBasic and Translational Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Maurizio PolanoExperimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico di Aviano IRCCS, Aviano, Italy.
Paola Del BiancoClinical Research Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Giulia PaselloDepartment of Surgery, Oncology, Gastroenterology, University of Padova, Padua, Italy.
Valentina GuarneriDepartment of Surgery, Oncology, Gastroenterology, University of Padova, Padua, Italy.
Stefano IndraccoloBasic and Translational Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy. stefano.indraccolo@iov.veneto.it.
Laura BonannoDepartment of Surgery, Oncology, Gastroenterology, University of Padova, Padua, Italy.

Funding

Istituto Oncologico Veneto 2017-5x1000 (MAGIC-2)Ministero della Salute Ricerca corrente 2024
6 · The paper itself

Abstract

Liquid biopsy has recently emerged as an important tool in clinical practice particularly for lung cancer patients. We retrospectively evaluated cell-free DNA analyses performed at our Institution by next generation sequencing methodology detecting the major classes of genetic alterations. Starting from the graphical representation of chromosomal alterations provided by the analysis software, we developed a support vector machine classifier to automatically classify chromosomal profiles as stable (SCP) or unstable (UCP). High concordance was found between our binary classification and tumor fraction evaluation performed using shallow whole genome sequencing. Among clinical features, UCP patients were more likely to have ≥ 3 metastatic sites and liver metastases. Longitudinal assessment of chromosomal profiles in 33 patients with lung cancer receiving immune checkpoint inhibitors (ICIs) showed that only patients that experienced early death or hyperprogressive disease retained or acquired an UCP within 3 weeks from the beginning of ICIs. UCP was not observed following ICIs among patients that experienced progressive disease or clinical benefit. In conclusion, our binary classification, applied to whole copy number alteration profiles, could be useful for clinical risk stratification during systemic treatment for non-small cell lung cancer patients.

Indexed as

Carcinoma, Non-Small-Cell LungDNA Copy Number VariationsLung NeoplasmsAgedAged, 80 and overFemaleHigh-Throughput Nucleotide SequencingHumansImmune Checkpoint InhibitorsLiquid BiopsyMaleMiddle AgedRetrospective StudiesSupport Vector MachineImmune Checkpoint InhibitorsCopy number alterationsImmunotherapyLiquid biopsyMachine learningTumor fraction

Identifiers

PMID39122833
PMCPMC11316016

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.